Skip to content

Study · Non-randomized trial · 1998

10 results

Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans.

Frank JW, Camilleri M, Thomforde GM, Dinneen SF, Rizza RA

Metabolism: clinical and experimental1 Jan 1998Cited by 12 (Europe PMC)

PMID9440470 (opens in a new tab)DOI10.1016/s0026-0495(98)90185-8 (opens in a new tab)PepBankPUB-09440470
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, postprandial glucose did not differ between glucagon infusion conditions and saline.

    In plain wordsIn nondiabetic people, postprandial blood glucose was similar with glucagon and saline infusions.

    Peptide
    Glucagon
    Outcome
    No significant changePostprandial glucose
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.65 or 3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    Despite marked differences in glucagon concentrations, postprandial glucose and insulin concentrations did not differ on any occasion.
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  2. 02HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, postprandial insulin did not differ between glucagon infusion conditions and saline.

    In plain wordsIn nondiabetic people, insulin levels after meals were similar with glucagon and saline infusions.

    Peptide
    Glucagon
    Outcome
    No significant changePostprandial insulin
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.65 or 3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    Despite marked differences in glucagon concentrations, postprandial glucose and insulin concentrations did not differ on any occasion.
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  3. 03HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, liquid gastric emptying was comparable with glucagon and saline infusions.

    In plain wordsIn nondiabetic people, liquids left the stomach at similar rates with glucagon and saline infusions.

    Peptide
    Glucagon
    Outcome
    No significant changeLiquid gastric emptying
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.65 or 3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    Although gastric emptying of liquids and solids was comparable on all three occasions,
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  4. 04HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, solid gastric emptying was comparable with glucagon and saline infusions.

    In plain wordsIn nondiabetic people, solids left the stomach at similar rates with glucagon and saline infusions.

    Peptide
    Glucagon
    Outcome
    No significant changeSolid gastric emptying
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.65 or 3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    Although gastric emptying of liquids and solids was comparable on all three occasions,
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  5. 05HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, high-dose glucagon slightly delayed systemic appearance of ingested glucose compared with saline.

    In plain wordsIn nondiabetic people, high-dose glucagon slightly delayed ingested glucose entering circulation compared with saline.

    Peptide
    Glucagon
    Outcome
    DecreaseSystemic appearance of ingested glucose at high dose
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  6. 06HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, low-dose glucagon did not delay systemic appearance of ingested glucose compared with saline.

    In plain wordsIn nondiabetic people, low-dose glucagon did not delay ingested glucose entering circulation compared with saline.

    Peptide
    Glucagon
    Outcome
    No significant changeSystemic appearance of ingested glucose at low dose
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.65 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  7. 07HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, high-dose glucagon decreased postprandial D-xylose concentrations compared with saline (P < .01).

    In plain wordsIn nondiabetic people, high-dose glucagon lowered D-xylose levels after meals compared with saline.

    Peptide
    Glucagon
    Outcome
    DecreasePostprandial D-xylose
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Gastrointestinal absorption · Gastrointestinal
    Studied dose
    3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose and a significant decrease (P < .01) in postprandial D-xylose concentrations, suggesting a delay in carbohydrate absorption.
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  8. 08HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, high-dose glucagon increased endogenous glucose production compared with saline (P < .05).

    In plain wordsIn nondiabetic people, high-dose glucagon increased the body's glucose production compared with saline.

    Peptide
    Glucagon
    Outcome
    IncreaseEndogenous glucose production
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    However, this was offset by an increase (P < .05) in endogenous glucose production, resulting in no difference in postprandial glucose appearance.
    2 context sentences
    Summary · context
    the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  9. 09HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, high-dose glucagon produced no difference in postprandial glucose appearance compared with saline.

    In plain wordsIn nondiabetic people, high-dose glucagon did not change total glucose appearance after meals compared with saline.

    Peptide
    Glucagon
    Outcome
    No significant changePostprandial glucose appearance
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    However, this was offset by an increase (P < .05) in endogenous glucose production, resulting in no difference in postprandial glucose appearance.
    2 context sentences
    Summary · context
    the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.
  10. 10HumanNon-randomized trialEfficacy outcome

    In nondiabetic humans, low-dose glucagon did not decrease postprandial D-xylose concentrations compared with saline.

    In plain wordsIn nondiabetic people, low-dose glucagon did not lower D-xylose levels after meals compared with saline.

    Peptide
    Glucagon
    Outcome
    No significant changePostprandial D-xylose at low dose
    Study

    n: not reported in source

    Comparator
    Saline infusion permitting glucagon suppression
    Outcome group
    Gastrointestinal absorption · Gastrointestinal
    Studied dose
    0.65 ng/kg/min · infusionAs given in this study (human).

    Source sentences

    Summary
    Although gastric emptying of liquids and solids was comparable on all three occasions, the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose and a significant decrease (P < .01) in postprandial D-xylose concentrations, suggesting…
    1 context sentence
    Summary · context
    either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.